Fusidic_acid_sodium_salt_LCMS_16991_MedChemExpress

===================================================================== *** End of Report ***
Instrument 1 4/20/2015 9:50:53 AM CYL(HPLC-09)
Page
1 of 1
Instrument 1 4/20/2015 9:51:19 AM CYL(HPLC-09)
Page
1 of 1
Data File D:\CHEM32\DATA\20150417\20150417 2015-04-17 09-32-31\065-3801.D Sample Name: CPK2015-417-06691 ===================================================================== Acq. Operator : CYL(HPLC-09) Seq. Line : 38 Acq. Instrument : Instrument 1 Location : Vial 65 Injection Date : 4/17/2015 9:27:50 PM Inj : 1 Inj Volume : 5.000 µl Acq. Method : D:\CHEM32\DATA\20150417\20150417 2015-04-17 09-32-31\5-80A(210NM).M Last changed : 4/17/2015 9:07:04 PM by CYL(HPLC-09) (modified after loading) Analysis Method : D:\CHEM32\METHODS\RP-HPLC\HY-310_9-H01P01,C2.M Last changed : 4/20/2015 9:50:52 AM by CYL(HPLC-09) (modified after loading) Catalog No : HY-A0027 Batch#06691 A-RP-93 Additional Info : Peak(s) manually integrated

Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:PMSF is an irreversible serine/cysteine protease inhibitor.In Vitro: PMSF (2 mM) inhibits carbachol–stimulated inositol phosphate accumulation in the presence of Li + by only 15%–19%.PMSF inhibition of phosphoinositide turnover is due to one or more steps following phosphoinositide breakdown [1]. PMSF inhibits the acylation of the inositol residue of GPI intermediates in bloodstream form T. brucei . PMSF inhihits the formntion of glycolipid C but does not inhibit fatty acid remodeling in vitro. PMSF inhihits GPI acylation and ethanolamine phosphatp addition in procyclic trypanosomes but not in Hela cells [2].In Vivo: PMSF (0.1 mL/10 g b.wt, i.p.) produces antinociception as indicated by the dose–responsive increase in % MPE in the tail–flick latency evaluation, but fails to produce a clear dose–responsive inhibition of locomotion. Mice receiving i.p. injections of PMSF exhibit cannabinoid effects that includes antinociception, hypothermia and immobility with ED 50 values of 86, 224 and 206mg/kg, respectively. PMSF (30 mg/kg) pretreatment potentiates the effects of anandamide on tail–flick response (antinociception),spontaneous activity and mobility by 5–, 10– and 8–fold, respectively [3].PROTOCOL (Extracted from published papers and Only for reference)Animal Administration: PMSF is dissolved in sesame oil.[3]Male ICR mice weighing 18 to 25 g are used in the assay. PMSF is dissolved in sesame oil and administered i.p. at a volume of 0.1 mL/10 g b.wt. PMSF is always administered 10 min before i.v. anandamide or vehicle injections. Mice are acclimated to the evaluation room overnight without interruption of food or water. After i.v. anandamide or vehicle administration each animal is evaluated as follows: tail–flick latency (antinociception) response at 5 min and spontaneous (locomotor) activity at 5 to 15 min; or core (rectal) temperature at 5 min and ring–immobility (catalepsy) at 5 to 10 min.References:[1]. Sekar, M.C. and B.D. Roufogalis, Differential effects of phenylmethanesulfonyl fluoride (PMSF) on carbachol and potassium stimulated phosphoinositide turnover and contraction in longitudinal smooth muscle of guinea pig ileum. Cell Calcium, 1984. 5(3): p.[2]. Guther, M.L., W.J. Masterson, and M.A. Ferguson, The effects of phenylmethylsulfonyl fluoride on inositol–acylation and fatty acid remodeling in African trypanosomes. J Biol Chem, 1994. 269(28): p. 18694–701.[3]. Compton, D.R. and B.R. Martin, The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity. J Pharmacol Exp Ther, 1997. 283(3): p. 1138–43.Product Name:PMSF Cat. No.:HY-B0496CAS No.:329-98-6Molecular Formula:C 7H 7FO 2S Molecular Weight:174.19Target:Proteasome Pathway:Metabolic Enzyme/Protease Solubility:10 mM in DMSOCaution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

Product Name:Fluvoxamine maleate CAS No.:61718-82-9Cat. No.:HY-B0103AProduct Data SheetMWt:434.41Formula:C19H25F3N2O6Purity :>98%Solubility:DMSO 87 mg/mL; Water <1y Mechanisms:Biological Activity:Fluvoxamine maleate is an antidepressant which functions pharmacologically as a selectivePathways:Neuronal Signaling; Target:SSRIs g ;mg/mL; Ethanol 87 mg/mLFluvoxamine maleate is an antidepressant which functions pharmacologically as a selectiveserotonin reuptake inhibitor.Target: SSRIs Fluvoxamine (maleate) is the maleate salt form of fluvoxamine, which is effective in inhibiting 5-HT uptake by blood platelets and brain synaptosomes. The antagonism by fluvoxamine of the reserpine-induced lowering of the pentamethylenetetrazole convulsive threshold can be regarded as due to an effect upon 5-HT uptake. In contrast to the effects of desmethylimipramine and imipramine, no stimulatory effects are found in rats when rapidly acting reserpine-like compounds are given following a dose of fluvoxamine [1]. fluvoxamine appears to improve combat-related PTSD References:[1]. Claassen, V., et al., Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor. Br JPharmacol, 1977. 60(4): p. 505-16.[2]. Escalona, R., et al., Fluvoxamine treatment in veterans with combat-related post-traumatic g []pp psymptoms but not depressive symptoms. The high attrition rate and lack of a placebo group limits the conclusions of our study. Controlled studies of fluvoxamine in the treatmen...stress disorder. Depress Anxiety, 2002. 15(1): p. 29-33.[3]. Ginsburg, B.C., J.W. Pinkston, and R.J. Lamb, The potency of fluvoxamine to reduce ethanol self-administration decreases with concurrent availability of food. Behav Pharmacol, 2012. 23(2): p.134-42.Caution: Not fully tested. For research purposes onlyMedchemexpress LLC18W i l k i n s o n W a y , P r i n c e t o n , N J 08540,U S AE m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c o m。

Product Name:Sivelestat sodium CAS No.:150374-95-1Cat No :HY-17443AProduct Data SheetCat. No.:HY 17443A MWt:456.44Formula:C20H21N2NaO7S Purity :>98%Solubility:Mechanisms:Biological Activity:Pathways:Metabolism/Protease; Target:Elastase DMSOSivelestat sodium(ONO5046; LY544349; EI546) is a competitive inhibitor of human neutrophil elastase(IC50 = 44 nM; Ki=200 nM); also inhibited leukocyte elastase obtained from rabbit, rat,hamster and mouse.IC50 value: 44 nM [1]Target: neutrophil elastase ONO-5046 did not inhibit trypsin, thrombin, plasmin, plasma kallikrein, pancreas kallikrein,chymotrypsin and cathepsin G even at 100 microM. In in vivo studies, ONO-5046 suppressed lung hemorrhage in hamster (ID50 = 82 micrograms/kg) by intratracheal administration and increase of skin capillary permeability in guinea pig (ID50=96mg/kg)by intravenous administration both of References:[1]. Kawabata K, et al. ONO-5046, a novel inhibitor of human neutrophil elastase. Biochem Biophys Res Commun 1991Jun 14;177(2):814-20skin capillary permeability in guinea pig (ID50 = 9.6 mg/kg) by intravenous administration, both of which were induced by human neutrophil elastase [1]. Sivelestat sodium hydrate is an anti-neutrophil elastase inhibitor and may be one of the treatment options for acute respiratory failure due to pneumocystis pneumonia in AIDS patients [2...Res Commun. 1991 Jun 14;177(2):814-20.[2]. Imokawa S, et al. Acute respiratory failure due to pneumocystis pneumonia successfully treated with combined use of sivelestat sodium hydrate. Nihon Kokyuki Gakkai Zasshi. 2008 Jun;46(6):461-5.Caution: Not fully tested. For research purposes onlyMedchemexpress LLC18 W i l k i n s o n W a y , P r i n c e t o n , N J 08540,U S AE m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c o m。